glp 1 agonists tirzepatide vs. Semaglutide: What You Should Know Frontiers | Clinical perspectives on
Description
This slowing effect is why Wegovy commonly causes gastrointestinal side effects
Follow the patient leaflet and ask your prescriber if you are unsure
In clinical trials, the drug causes an average weight reduction of up to 20.9% in a year and a half
On average, individuals treated with Tirzepatide can lose a significant percentage of their body weight, sometimes reaching 10-20% or more, depending on the dosage and duration of treatment
Week 48: Phase 2 Results Kept Building At 48 weeks in the same Phase 2 trial, the least-squares mean body-weight change was 17.1% in the combined 4 mg group, 22.8% in the combined 8 mg group, and 24.2% in the 12 mg group, compared with 2.1% for placebo
